Reconvan is developed by Jagiellonian University.

What development phase is Reconvan in?

Reconvan is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Reconvan

Jagiellonian University · FDA-approved active Small molecule Quality 0/100

Reconvan, marketed by Jagiellonian University, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its current market presence, leveraging the unique mechanism of action that differentiates it from competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Reconvan
Also known as	oligopeptic immunostimulatory diet
Sponsor	Jagiellonian University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Postoperative Enteral Immunonutrition in Gastric Cancer (PHASE3)
The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery (PHASE4)
Standard and Immunostimulating Enteral Nutrition in Surgical Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results